메뉴 건너뛰기




Volumn 99, Issue 8, 2010, Pages 3302-3321

An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics

Author keywords

Biotechnology; Immunology; Particle size; Protein aggregation; Protein formulation

Indexed keywords

ALGLUCOSIDASE; ASPARAGINASE; CETUXIMAB; ETANERCEPT; GLUCOSIDASE; IMIGLUCERASE; INFLIXIMAB; LARONIDASE; OFATUMUMAB; OKT 3; PANITUMUMAB; UNCLASSIFIED DRUG; DRUG; NANOPARTICLE; PROTEIN;

EID: 77955100181     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22097     Document Type: Review
Times cited : (295)

References (31)
  • 1
    • 33748041958 scopus 로고    scopus 로고
    • Effect of protein aggregates: An immunologic perspective
    • Rosenberg AS. 2006. Effect of protein aggregates: An immunologic perspective. AAPS J 8:E501-E507.
    • (2006) AAPS J , vol.8
    • Rosenberg, A.S.1
  • 2
    • 68949085124 scopus 로고    scopus 로고
    • Protein aggregation: Pathways, induction factors and analysis
    • Mahler H-C, Freiss W, Grauschopf U, Keise S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98:2909-2934.
    • (2009) J Pharm Sci , vol.98 , pp. 2909-2934
    • Mahler, H.-C.1    Freiss, W.2    Grauschopf, U.3    Keise, S.4
  • 3
    • 33748742268 scopus 로고    scopus 로고
    • Is any measurement method optimal for all aggregate sizes and types?
    • Philo JS. 2006. Is any measurement method optimal for all aggregate sizes and types? AAPS J 8:E564-E571.
    • (2006) AAPS J , vol.8
    • Philo, J.S.1
  • 4
    • 69249206868 scopus 로고    scopus 로고
    • A critical review of methods for size characterization of non-particulate protein aggregates
    • Philo JS. 2009. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 10:359-372.
    • (2009) Curr Pharm Biotechnol , vol.10 , pp. 359-372
    • Philo, J.S.1
  • 5
    • 55849153131 scopus 로고    scopus 로고
    • Protein particulate issues in biologics development
    • Das T, Nema S. 2008. Protein particulate issues in biologics development. Am Pharm Rev 11(4):52-57.
    • (2008) Am Pharm Rev , vol.11 , Issue.4 , pp. 52-57
    • Das, T.1    Nema, S.2
  • 6
    • 69249215475 scopus 로고    scopus 로고
    • A critical review of analytical methods for subvisible and visible particles
    • Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10:378-381.
    • (2009) Curr Pharm Biotechnol , vol.10 , pp. 378-381
    • Narhi, L.O.1    Jiang, Y.2    Cao, S.3    Benedek, K.4    Shnek, D.5
  • 8
    • 0033376410 scopus 로고    scopus 로고
    • The scientific basis for visible particle inspection
    • Knapp JZ. 1999. The scientific basis for visible particle inspection. PDA J Pharm Sci Tech 53:291-302.
    • (1999) PDA J Pharm Sci Tech , vol.53 , pp. 291-302
    • Knapp, J.Z.1
  • 9
    • 10944231251 scopus 로고    scopus 로고
    • A risk-based approach to immunogenicity concerns of therapeutic protein products. Part II: Considering host-specific and product-specific factors impacting immunogenicity
    • Rosenberg AS, Worobec A. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part II: Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int 17(12):34-42.
    • (2004) BioPharm Int , vol.17 , Issue.12 , pp. 34-42
    • Rosenberg, A.S.1    Worobec, A.2
  • 10
    • 32944459736 scopus 로고    scopus 로고
    • Factors influencing the immunogenicity of therapeutic proteins
    • Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20:vi3-vi9.
    • (2005) Nephrol Dial Transplant , vol.20
    • Schellekens, H.1
  • 11
    • 0030856842 scopus 로고    scopus 로고
    • Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-a) in normal and transgenic mice
    • DOI 10.1023/A:1012193326789
    • Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of Interferon alpha (IFN-a) in normal and transgenic mice. Pharm Res 14:1472-1478. (Pubitemid 27481082)
    • (1997) Pharmaceutical Research , vol.14 , Issue.10 , pp. 1472-1478
    • Braun, A.1    Kwee, L.2    Labow, M.A.3    Alsenz, J.4
  • 12
  • 13
    • 33646546740 scopus 로고    scopus 로고
    • Antibody response to aggregated human Interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation
    • Hermeling S, Schellekens H, Maas C, Gebbink MFBG, Crommelin DJA, Jiskoot W. 2006. Antibody response to aggregated human Interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95:1084-1096.
    • (2006) J Pharm Sci , vol.95 , pp. 1084-1096
    • Hermeling, S.1    Schellekens, H.2    Maas, C.3    Gebbink, M.F.B.G.4    Crommelin, D.J.A.5    Jiskoot, W.6
  • 14
    • 32644434554 scopus 로고    scopus 로고
    • Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia a mice
    • DOI 10.1002/jps.20529
    • Purohit VS, Middaugh CR, Balasubramanian SV. 2006. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci 95:358-371. (Pubitemid 43241978)
    • (2006) Journal of Pharmaceutical Sciences , vol.95 , Issue.2 , pp. 358-371
    • Purohit, V.S.1    Middaugh, C.R.2    Balasubramanian, S.V.3
  • 15
    • 46149124807 scopus 로고    scopus 로고
    • How to predict and prevent the immunogenicity of therapeutic proteins
    • Schellekens H. 2008. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14:191-202.
    • (2008) Biotechnol Annu Rev , vol.14 , pp. 191-202
    • Schellekens, H.1
  • 16
    • 17644378667 scopus 로고    scopus 로고
    • Immunogenicity of engineered antibodies
    • Hwang WYK, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10.
    • (2005) Methods , vol.36 , pp. 3-10
    • Hwang, W.Y.K.1    Foote, J.2
  • 17
    • 55749109195 scopus 로고    scopus 로고
    • Shaken, not stirred - Mechanical stress testing of an IgG1 antibody
    • Kiese S, Pappenberger A, Friess W, Mahler H-C. 2008. Shaken, not stirred - Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347-4366.
    • (2008) J Pharm Sci , vol.97 , pp. 4347-4366
    • Kiese, S.1    Pappenberger, A.2    Friess, W.3    Mahler, H.-C.4
  • 18
    • 68949135230 scopus 로고    scopus 로고
    • Immunogenicity of aggregates of recombinant human growth hormone in mouse models
    • Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98:3247-3264.
    • (2009) J Pharm Sci , vol.98 , pp. 3247-3264
    • Fradkin, A.H.1    Carpenter, J.F.2    Randolph, T.W.3
  • 19
    • 3843149585 scopus 로고    scopus 로고
    • Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans
    • Bugelski PJ, Treacy G. 2004. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 6:10-16.
    • (2004) Curr Opin Mol Ther , vol.6 , pp. 10-16
    • Bugelski, P.J.1    Treacy, G.2
  • 20
    • 67349088299 scopus 로고    scopus 로고
    • How to systematically evaluate immunogenicity of therapeutic proteins - Regulatory considerations
    • 10.1016/j.nbt.2009.03.012
    • Jahn E-M, Schneider C. 2009. How to systematically evaluate immunogenicity of therapeutic proteins - Regulatory considerations. New Biotechnol 25:280-286. 10.1016/j.nbt.2009.03.012.
    • (2009) New Biotechnol , vol.25 , pp. 280-286
    • Jahn, E.-M.1    Schneider, C.2
  • 21
    • 16844367771 scopus 로고    scopus 로고
    • A risk-based approach to immunogenicity concerns of therapeutic protein products. Part III: Effects of manufacturing changes on immunogenicity and the utility of animal immunogenicity studies
    • Rosenberg AS, Worobec A. 2005. A risk-based approach to immunogenicity concerns of therapeutic protein products. Part III: Effects of manufacturing changes on immunogenicity and the utility of animal immunogenicity studies. BioPharm Int 18(1):32-36.
    • (2005) BioPharm Int , vol.18 , Issue.1 , pp. 32-36
    • Rosenberg, A.S.1    Worobec, A.2
  • 24
    • 69249213763 scopus 로고    scopus 로고
    • Separation and characterization of protein aggregates and particles by field flow fractionation
    • Cao S, Pollastrini J, Jiang Y. 2009. Separation and characterization of protein aggregates and particles by field flow fractionation. Curr Pharm Biotechnol 10:382-390.
    • (2009) Curr Pharm Biotechnol , vol.10 , pp. 382-390
    • Cao, S.1    Pollastrini, J.2    Jiang, Y.3
  • 26
    • 0029387359 scopus 로고    scopus 로고
    • Particle size analysis. A comparative study of various methods I
    • Etzler FM, Sanderson MS. 1997. Particle size analysis. A comparative study of various methods I. Part Part Syst Charact 12:217-224.
    • (1997) Part Part Syst Charact , vol.12 , pp. 217-224
    • Etzler, F.M.1    Sanderson, M.S.2
  • 27
    • 0031375753 scopus 로고    scopus 로고
    • Particle size analysis. A comparative study of various methods II
    • Etzler FM, Sanderson MS. 1997. Particle size analysis. A comparative study of various methods II. Part Part Syst Charact 12:278-282.
    • (1997) Part Part Syst Charact , vol.12 , pp. 278-282
    • Etzler, F.M.1    Sanderson, M.S.2
  • 28
    • 68949132582 scopus 로고    scopus 로고
    • Quantitation of protein particles in parenteral solutions using Micro-Flow Imaging
    • Huang CT, Sharma D, Oma P, Krishnamurthy R. 2008. Quantitation of protein particles in parenteral solutions using Micro-Flow Imaging. J Pharm Sci 98:3058-3071.
    • (2008) J Pharm Sci , vol.98 , pp. 3058-3071
    • Huang, C.T.1    Sharma, D.2    Oma, P.3    Krishnamurthy, R.4
  • 29
    • 65349153327 scopus 로고    scopus 로고
    • Flow microscopy for particulate analysis in parenteral and pharmaceutical fluids
    • Sharma D, King D, Moore P, Oma P, Thomas D. 2007. Flow microscopy for particulate analysis in parenteral and pharmaceutical fluids. Eur J Parenteral Pharm Sci 12:97-101.
    • (2007) Eur J Parenteral Pharm Sci , vol.12 , pp. 97-101
    • Sharma, D.1    King, D.2    Moore, P.3    Oma, P.4    Thomas, D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.